New drug TORL-3-600 tested in advanced cancer patients for first time
NCT ID NCT05948826
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 31 times
Summary
This early-stage study tests a new drug called TORL-3-600 in 70 adults with advanced solid tumors or colorectal cancer that has not responded to other treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have measurable disease and adequate organ function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fort Wayne Medical Oncology and Hematology Inc.
Fort Wayne, Indiana, 46845, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
McGill University Health Centre
Montreal, Quebec, H4A 3J1, Canada
-
Providence Medical Foundation
Fullerton, California, 92835, United States
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute-Tennessee
Nashville, Tennessee, 37203, United States
-
UCLA - JCCC Clinical Research Unit
Los Angeles, California, 90095, United States
-
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Washington University School of Medicine-Siteman Cancer Center
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.